- -- 29 September 2009
- immatics appoints Carsten Reinhardt as Chief Medical Officer
- -- 10 August 2009
- immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide
- -- 17 June 2009
- immatics biotechnologies significantly improves XPRESIDENT™ technology platform
- -- 02 March 2009
- immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer
- -- 26 January 2009
- immatics wins 29th German Industry's Innovation Award (Innovationspreis der deutschen Wirtschaft)
- -- 23 January 2009
- Dr. Jürgen Frisch (Chief Medical Officer) to leave immatics
